drugset / Trial / NCT02326740

An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum

NCT02326740

Phase 3 Terminated 9 enrolled XOMA (US) LLC
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The study will evaluate the efficacy and safety of gevokizumab in treating active ulcers of pyoderma gangrenosum (PG).

Timeline

Start
2014-12
Primary completion
2016-03
Completion
2016-03

Drugs

EvaluationDrugModalityDoseRoute
Subject gevokizumab Monoclonal antibody Subcutaneous

Indications